Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkaf010
Abstract: Abstract Background Tecovirimat is an antiviral drug that was used compassionately for treating mpox in high-income settings during the 2022 global outbreak. Randomized controlled trials of its efficacy have not yet been completed. Objectives To… read more here.
Keywords: underscores ongoing; tecovirimat; clinical equipoise; ongoing clinical ... See more keywords